Hypertension in people with diabetes and the metabolic syndrome: Pathophysiologic insights and therapeutic update

被引:10
|
作者
Ganne S. [1 ]
Arora S.K. [1 ]
Dotsenko O. [1 ]
McFarlane S.I. [1 ]
Whaley-Connell A. [1 ]
机构
[1] Department of Internal Medicine, Division of Nephrology, University of Missouri-Columbia School of Medicine, Columbia, MO 65212, One Hospital Drive
关键词
Chronic Kidney Disease; Metabolic Syndrome; Atrial Natriuretic Peptide; Irbesartan; RAAS Blockade;
D O I
10.1007/s11892-007-0033-3
中图分类号
学科分类号
摘要
Hypertension (HTN) and type 2 diabetes mellitus (T2DM) are emerging as epidemics of the 21st century and are important components of the metabolic syndrome (MS). Evidence demonstrates a relationship between HTN, T2DM, and several vascular and metabolic abnormalities that are components of the MS. HTN affects nearly 70 million Americans and over one billion worldwide; likewise, the MS affects 44% of the US population above the age of 60 years and is rapidly increasing. HTN associated with the MS has certain pathophysiologic characteristics that provide clinical challenges. There is growing evidence that tissue activation of the renin-angiotensin system contributes to endothelial dysfunction, microalbuminuria, insulin resistance, and subsequent increased risk for cardiovascular and chronic kidney disease. The notion that HTN is a metabolic as well as a vascular disease provides a new treatment paradigm. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码:208 / 217
页数:9
相关论文
共 50 条
  • [21] Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome
    Srikanth, Sundararajan
    Deedwania, Prakash
    CURRENT HYPERTENSION REPORTS, 2016, 18 (10)
  • [22] Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome
    Sundararajan Srikanth
    Prakash Deedwania
    Current Hypertension Reports, 2016, 18
  • [23] Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome
    Cottrell, DA
    Marshall, BJ
    Falko, JM
    CURRENT OPINION IN CARDIOLOGY, 2003, 18 (04) : 301 - 308
  • [24] Ocimum sanctum:: A therapeutic role in diabetes and the metabolic syndrome
    Kapoor, Shailendra
    HORMONE AND METABOLIC RESEARCH, 2008, 40 (04) : 296 - 296
  • [25] Exfoliation syndrome: new genetic and pathophysiologic insights
    Sein, Julia
    Galor, Anat
    Sheth, Anoop
    Kruh, Jonathan
    Pasquale, Louis R.
    Karp, Carol L.
    CURRENT OPINION IN OPHTHALMOLOGY, 2013, 24 (02) : 167 - 174
  • [26] Pathophysiologic therapeutic targets in hypertension: a cardiological point of view
    Fragasso, Gabriele
    Maranta, Francesco
    Montanaro, Claudia
    Salerno, Anna
    Torlasco, Camilla
    Margonato, Alberto
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (02) : 179 - 193
  • [27] Methylene blue and cirrhosis: Pathophysiologic insights, therapeutic dilemmas
    Fallon, MB
    ANNALS OF INTERNAL MEDICINE, 2000, 133 (09) : 738 - 740
  • [28] Thiamine Deficiency: An Update of Pathophysiologic Mechanisms and Future Therapeutic Considerations
    Abdou, Eman
    Hazell, Alan S.
    NEUROCHEMICAL RESEARCH, 2015, 40 (02) : 353 - 361
  • [29] Update on the therapeutic role of metformin in the management of polycystic ovary syndrome: Effects on pathophysiologic process and fertility outcomes
    Brand, Kerstin M. G.
    Gottwald-Hostalek, Ulrike
    Andag-Silva, Aimee
    WOMENS HEALTH, 2025, 21
  • [30] SPASTIC COLON SYNDROME - THERAPEUTIC AND PATHOPHYSIOLOGIC CONSIDERATIONS
    LECHIN, F
    VANDERDIJS, B
    BENTOLILA, A
    PENA, F
    JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 17 (07): : 431 - 440